

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/647,268	08/20/2003	Teruko Osumi	0155.02	2068
25278 75	7590 02/10/2005		EXAMINER	
USDA-ARS-OFFICE OF TECHNOLOGY TRANSFER			IBRAHIM, MEDINA AHMED	
	ISORS OFFICE		ART UNIT	PAPER NUMBER
WESTERN REGIONAL RESEARCH CENTER			ARTONII	PAPER NUMBER
800 BUCHANAN ST			1638	
ALBANY, CA 94710			DATE MAILED: 02/10/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/647,268	OSUMI ET AL.				
		Examiner	Art Unit				
		Medina A Ibrahim	1638				
Period 1	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence ad	ddress			
THE - Ext afte - If th - If N - Fai Any	MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1.13 or SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period of the period for reply within the set or extended period for reply will, by statute or reply received by the Office later than three months after the mailing ned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from the application to become ABANDONE	nely filed s will be considered time the mailing date of this of D (35 U.S.C. § 133).	ly. communication.			
Status							
1)⊠	Responsive to communication(s) filed on 20 A	<u>ugust 2003</u> .	•				
2a)[_	This action is <b>FINAL</b> . 2b) ☐ This	action is non-final.					
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposi	tion of Claims	•					
4)⊠ 5)□ 6)□ 7)□	Claim(s) 1-15 is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) is/are rejected.	vn from consideration.					
Applica	tion Papers						
9)[	The specification is objected to by the Examine	r. ·					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)[	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	, , , , , , , , , , , , , , , , , , , ,		• •			
Priority	under 35 U.S.C. § 119						
12) <u> </u>	Acknowledgment is made of a claim for foreign All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been receive u (PCT Rule 17.2(a)).	on No In this National	Stage			
Attachme	nt(s)						
1) 🔲 Noti	ce of References Cited (PTO-892)	4) Interview Summary					
2) 🔲 Noti 3) 🔲 Info	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:		O-152)			

Application/Control Number: 10/647,268

Art Unit: 1638

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-9 and 11-15, drawn to an isolated nucleic acid molecule encoding a disease resistance polypeptide, plant, and a plant transformation method, classified in class 800, subclass 279, for example.
- II. Claim 10, drawn to an isolated polypeptide, classified in class 530, subclass 370, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process. (MPEP § 806.05(f)). In the instant case, the polypeptide of Group II can be made by another and materially different process, such as chemical synthesis. For instance, the polypeptide can be isolated using affinity chromatography. In addition, the nucleic acid of Group I is patentably distinct from the polypeptide of Group II because polypeptides are composed of amino acids while the nucleic acids are composed of purines /pyrimidine units, which are structurally different molecules; any relationship between a nucleic acid and a polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, a nucleic acid of Group I

Application/Control Number: 10/647,268

Art Unit: 1638

does not necessarily encode a polypeptide of Group II. For example, a nucleic acid that hybridizes to SEQ ID NO: 1 under unspecified hybridization conditions (claim 1, part c) does not encode SEQ ID NO: 2. Therefore, the inventions of Groups I and II are patentably distinct.

Furthermore, searching the inventions of Groups I and II together would impose a serious search burden. In the instant case, the search of the nucleic acids and the polypeptides is not coextensive. In addition, the scope of the polypeptides encompasses polypeptides having 93% identity to the sequence identified. This search requires an extensive analysis of the art retrieved in a sequence search and will require an in-depth analysis of technical literature. The scope of the nucleic acid claims extend beyond the nucleic acid that encodes the claimed polypeptide as discussed above.

Therefore, it would be burdensome to search the inventions of Groups I and II together.

Because these inventions are distinct for the reasons set forth above and have acquired a separate status in the art as shown by their different classifications and their recognized divergent subject matter and because the literature search required for the groups is not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 10/647,268

Art Unit: 1638

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM. Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor. Dr. Amy Nelson, can be reached at (571) 272-0804.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

2/4/05

Mai

MEDIMA A. IBRAHIM PATENT EXAMINER

Meduis A-Moral